Literature DB >> 10828047

Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population.

E Beutler1, T Gelbart.   

Abstract

Pyruvate kinase (PK) deficiency is the most common cause of hereditary nonspherocytic hemolytic anemia. The prevalence of this deficiency is unknown, though some estimates have been made based on the frequency of low red cell PK activity in the population. An additional 20 patients with hereditary nonspherocytic hemolytic anemia caused by PK deficiency have been genotyped. One previously unreported mutation 1153C-->T (R385W) was encountered. The relative frequency of PK mutations in patients with hemolytic anemia caused by PK deficiency was calculated from the 18 white patients reported here and from 102 patients previously reported in the literature. DNA samples from 3785 subjects from different ethnic groups have been screened for the 4 more frequently encountered mutations-c.1456 C-->T(1456T), c.1468 C-->T(1468T), c.1484 C-->T(1484T), and c.1529 G6A (1529A)-by allele-specific oligonucleotide hybridization. Among white patients the frequency of the 1456T mutation was 3.50 x 10(-3); that of the 1529A mutation was 2.03 x 10(-3). Among African Americans the frequency of the 1456T mutation was 3.90 x 10(-3) The only mutation found in the limited number of Asians tested was 1468T at a frequency of 7.94 x 10(-3). Based on the gene frequency of the 1529A mutation in the white population and on its relative abundance in patients with hemolytic anemia caused by PK deficiency, the prevalence of PK deficiency is estimated at 51 cases per million white population. This number would be increased by inbreeding and decreased by failure of patients with PK deficiency to survive.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828047

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Anemia in the Neonate: The Differential Diagnosis and Treatment.

Authors:  Michele L Nassin; Gabrielle Lapping-Carr; Jill L O de Jong
Journal:  Pediatr Ann       Date:  2015-07       Impact factor: 1.132

2.  Function and dysfunction.

Authors:  Narla Mohandas
Journal:  Blood       Date:  2018-05-17       Impact factor: 22.113

3.  Erythrocytic pyruvate kinase mutations causing hemolytic anemia, osteosclerosis, and seconday hemochromatosis in dogs.

Authors:  G Inal Gultekin; K Raj; P Foureman; S Lehman; K Manhart; O Abdulmalik; U Giger
Journal:  J Vet Intern Med       Date:  2012 Jul-Aug       Impact factor: 3.333

4.  Hemolytic anemia with null PKLR mutations identified using whole exome sequencing and cured by hematopoietic stem cell transplantation combined with splenectomy.

Authors:  M Kim; J Park; J Lee; W Jang; H Chae; H Choi; J Kim; A Kwon; J-W Lee; B Cho; Y Kim; N-G Chung
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

5.  Alu element insertion in PKLR gene as a novel cause of pyruvate kinase deficiency in Middle Eastern patients.

Authors:  Harry Lesmana; Lisa Dyer; Xia Li; James Denton; Jenna Griffiths; Satheesh Chonat; Katie G Seu; Matthew M Heeney; Kejian Zhang; Robert J Hopkin; Theodosia A Kalfa
Journal:  Hum Mutat       Date:  2018-01-11       Impact factor: 4.878

6.  Red cell pyruvate kinase deficiency in neonatal jaundice cases in India.

Authors:  Prabhakar S Kedar; Prashant Warang; Roshan B Colah; Dipika Mohanty
Journal:  Indian J Pediatr       Date:  2006-11       Impact factor: 1.967

7.  Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency.

Authors:  Paola Bianchi; Elisa Fermo; Bertil Glader; Hitoshi Kanno; Archana Agarwal; Wilma Barcellini; Stefan Eber; James D Hoyer; David J Kuter; Tabita Magalhães Maia; Maria Del Mar Mañu-Pereira; Theodosia A Kalfa; Serge Pissard; José-Carlos Segovia; Eduard van Beers; Patrick G Gallagher; David C Rees; Richard van Wijk
Journal:  Am J Hematol       Date:  2018-11-28       Impact factor: 10.047

8.  Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency.

Authors:  Maria Garcia-Gomez; Andrea Calabria; Maria Garcia-Bravo; Fabrizio Benedicenti; Penelope Kosinski; Sergio López-Manzaneda; Collin Hill; María Del Mar Mañu-Pereira; Miguel A Martín; Israel Orman; Joan-LLuis Vives-Corrons; Charles Kung; Axel Schambach; Shengfang Jin; Juan A Bueren; Eugenio Montini; Susana Navarro; Jose C Segovia
Journal:  Mol Ther       Date:  2016-05-03       Impact factor: 11.454

9.  Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme.

Authors:  Nestor W Meza; Maria E Alonso-Ferrero; Susana Navarro; Oscar Quintana-Bustamante; Antonio Valeri; Maria Garcia-Gomez; Juan A Bueren; Jose M Bautista; Jose C Segovia
Journal:  Mol Ther       Date:  2009-09-15       Impact factor: 11.454

10.  Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency.

Authors:  Paola Bianchi; Elisa Fermo; Kimberly Lezon-Geyda; Eduard J van Beers; Holmes D Morton; Wilma Barcellini; Bertil Glader; Satheesh Chonat; Yaddanapudi Ravindranath; Peter E Newburger; Nina Kollmar; Jenny M Despotovic; Madeleine Verhovsek; Mukta Sharma; Janet L Kwiatkowski; Kevin H M Kuo; Marcin W Wlodarski; Hassan M Yaish; Susanne Holzhauer; Heng Wang; Joachim Kunz; Kathryn Addonizio; Hasan Al-Sayegh; Wendy B London; Oliver Andres; Richard van Wijk; Patrick G Gallagher; Rachael F F Grace
Journal:  Am J Hematol       Date:  2020-03-06       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.